Supernus Pharmaceuticals | Innovating CNS Treatments
Supernus, a biopharmaceutical company, develops CNS disease treatments. Transforming patient care with cutting-edge therapies and strategic partnerships.
Overview
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company based in Rockville, Maryland, that develops and commercializes treatments for central nervous system (CNS) diseases. The company markets several products in the United States, including Qelbree® for attention deficit/hyperactivity disorder (ADHD) in children, Trokendi XR® for migraine prophylaxis and epilepsy treatment, Oxtellar XR® for epilepsy, Apokyn® for advanced Parkinson’s disease, Myobloc® for cervical dystonia and chronic sialorrhea, and Xadago® as an adjunctive treatment for Parkinson’s disease. Supernus also has a pipeline of product candidates aimed at addressing significant market needs in the CNS sector, such as SPN-812 for adult ADHD, an apomorphine infusion pump for hypomobility in Parkinson’s disease, SPN-820 for treatment-resistant depression, and SPN-817 for epilepsy.
Details
- Category
- Pharmaceutical Manufacturing
- Headquarters
- Rockville, Maryland
- Type
- Public Company
- Founded
- 2005
- Followers
- 24,554
- Specialties
- CNS, Epilepsy, Migraine, Parkinson's Disease, Cervical Dystonia, and Chronic Sialorrhea
- Locations
- 9715 Key West Ave Rockville, Maryland 20850, US